Connect Biopharma Holdings (CNTB) Long-Term Investments (2022)
Connect Biopharma Holdings (CNTB) posted Long-Term Investments of $9.2 million for Q4 2022, down 58.55% sequentially from $22.3 million in Q2 2022.
Connect Biopharma Holdings (CNTB) Long-Term Investments (2022) Analysis & Trends
Connect Biopharma Holdings has reported Long-Term Investments for 1 years, with the latest figure at $9.2 million in Q4 2022.
- Quarterly Long-Term Investments changed N/A year-over-year to $9.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $9.2 million (changed N/A YoY) and the FY2022 annual result came in at $9.4 million, changed N/A from the prior year.
- Long-Term Investments slipped to $9.2 million in Q4 2022 per CNTB's latest filing, from $22.3 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $22.3 million in Q2 2022 and troughed at $9.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 9.24 Mn |
| Jun 30, 2022 | 22.30 Mn |